m+Medelevator.RU
← Поиск публикаций
Hereditas · 2025

Impact of early blood purification on serum inflammatory mediators and hemorheology in severe acute pancreatitis.

СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Xiao Jing, Li Bo

Аннотация

BACKGROUND: Patients with severe acute pancreatitis (SAP) often experience systemic inflammatory responses and microcirculatory disturbances, for which existing treatments have limited intervention effects.

OBJECTIVES: It aimed to investigate the impact of early blood purification on serum inflammatory mediators, hemorheological parameters, and clinical prognosis in patients with SAP.

METHODS: 120 patients with SAP were randomly grouped: observation group (OG) (routine treatment + early continuous veno-venous hemodiafiltration) and control group (CG) (routine treatment). The time to clinical symptom improvement, hemorheological parameters [whole blood viscosity (WBV), plasma viscosity (PV), hematocrit, and platelet adhesion rate], and inflammatory mediators were compared. Multivariate logistic regression analysis (MLRA) was used to identify prognostic factors.

RESULTS: The OG had markedly shorter times to symptom relief for fever, abdominal pain, and abdominal distension (all P < 0.001) and a higher cure rate (P = 0.012); The levels of C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), as well as WBV and PV, were more markedly improved (all P < 0.01). Multivariate analysis suggested that peak CRP (OR = 1.01, P < 0.001) and peak TNF-α (OR = 1.02, P = 0.003) maintained independent predictive value, and all hemorheological parameters were confirmed as independent prognostic factors.

CONCLUSION: Early blood purification can effectively improve the inflammatory response and hemodynamics in patients with SAP, with its efficacy influenced by multiple factors, including disease severity, intensity of inflammatory response, and hemorheological status.

CLINICAL TRIAL NUMBER: Not applicable.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты